![Shunichi Morimoto](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shunichi Morimoto
Plus aucun poste en cours
Fortune : 2 M $ au 31/05/2024
Profil
Shunichi Morimoto was the Chairman of Institute of Immunology Co., Ltd.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
PHOENIXBIO CO., LTD.
12,56% | 31/03/2023 | 506 000 ( 12,56% ) | 2 M $ | 31/05/2024 |
Anciens postes connus de Shunichi Morimoto
Sociétés | Poste | Fin |
---|---|---|
Institute of Immunology Co., Ltd.
![]() Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | Président | - |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 1 |
---|---|
Institute of Immunology Co., Ltd.
![]() Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | Health Technology |